AcuraStem

AcuraStem is a near-to-clinic, patient-based therapeutics company advancing treatments for ALS, FTD and additional neurodegenerative indications.

AcuraStem harnesses advanced cellular reprogramming and artificial intelligence technologies to transform the standard of care for neurodegenerative diseases through patient-specific treatment. Go to acurastem.com to find out more.

02/02/2026

If you want a therapy that can move the needle for more than a narrow subgroup of ALS and FTD patients, you have to start with patients.

AcuraStem’s iNeuroRx® platform creates patient-derived human neurons and supporting cells.
Then we measure disease biology in human cells and advance therapies built for the broader ALS and FTD community.
Learn more at acurastem.com

01/24/2026

The biggest takeaway from the 16th ALS Research Summit?

The mouse model era is over.

Our presentation on SYF2 demonstrated that we can rescue neuronal function by targeting the spliceosome directly in human cells, and close the gap between discovery and the clinic.
The future of ALS treatment is patient-derived.

Follow our progress at acurastem.com

*OTherapeutics

01/23/2026

A result that looks “effective” is useless if it’s unsafe in human neurons. iNeuroRx® is AcuraStem’s patient-derived human neuron platform and the gold-standard for testing efficacy and safety in the cells most relevant to neurodegenerative disease.

Learn more at: acurastem.com

01/22/2026

Today at the 16th ALS Network Research Summit in Pasadena, AcuraStem Associate Vice President, Discovery and Early Development Dr. Wen-Hsuan Chang is presenting new research on SYF2-targeting A*Os.

In a joint presentation with Justin Ichida's lab at USC, Wen will detail how suppressing SYF2 can restore normal TDP-43 function. This work is powered by the iNeuroRx® platform, the gold standard for discovering novel, effective, and broadly-acting treatments. By leveraging patient-derived neurons, the platform enables these scientific findings to translate directly into potential therapies.

Stop by our poster sessions to learn more about our patient-based ALS models and A*O therapies. AcuraStem is on-site and ready to collaborate.

Find out more at acurastem.com

*OTherapies

01/15/2026

Behind every AcuraStem breakthrough is a team focused on turning insights from patient-derived models into treatments for people living with ALS and FTD. In 2026, we continue to advance work built on iNeuroRx® and antisense approaches focused on key drivers of neurodegeneration.

Stay informed on AcuraStem news and opportunities: acurastem.com/ -form

01/06/2026

iNeuroRx® builds cellular disease models derived from patients with ALS and FTD so AcuraStem can study human neurodegeneration directly in the lab. These models help our team find high-value targets and design antisense therapies, including programs focused on genes such as UNC13A.

Explore the gold standard for discovering novel, effective and broadly acting treatments at acurastem.com

01/02/2026

AcuraStem is delivering high-impact ALS therapeutics.
Studying disease in neurons from real patients helps us discover targeted therapies that are more likely to work across diverse forms of neurodegenerative disease.

Learn more at acurastem.com

12/24/2025

In 2025, support from clinicians, advocates, and research partners helped AcuraStem use iNeuroRx® to expand patient-derived ALS and FTD models and keep its antisense programs, like UNC13A and SYF2, moving toward clinical trials.

Thank you for backing patient-based science focused on faster, more effective treatments for people living with ALS and FTD. Warm holiday wishes and a hopeful new year from team at AcuraStem.

12/18/2025

iNeuroRx® builds cellular disease models derived from patients for ALS and FTD, so AcuraStem can study human neurodegeneration directly in the lab, find high-value targets and design antisense therapies such as its UNC13A program.

Explore this cutting-edge technology at: acurastem.com

12/08/2025

Be part of the next generation of neurodegenerative research.
Stay informed on new discoveries, technology updates, and partnership opportunities.

Keep up-to-date with AcuraStem at acurastem.com/ -form

12/05/2025

AcuraStem - ALS drug discovery built directly in neurons derived from patients.

Most neurodegenerative research still starts in models that don’t reflect the biology of the people they’re meant to help. At AcuraStem, we take a different approach. Our iNeuroRX® platform uses patient-derived neurons to identify therapies grounded in human biology from the outset. That means fewer dead ends, and more meaningful progress for ALS and other neurodegenerative diseases.

Meet the team today at the 2025 ALS/MND conference in San Diego.
AcuraStem is on-site and ready to connect.

Find out more at acurastem.com

12/02/2025

AcuraStem is developing treatments for ALS and FTD using patient-derived cell models and our iNeuroRx® technology platform. Studying disease in neurons from real patients helps us discover targeted therapies that are more likely to work across diverse forms of neurodegenerative disease.

Learn more: acurastem.com

Address

Monrovia, CA

Website

http://www.acurastem.com/

Alerts

Be the first to know and let us send you an email when AcuraStem posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to AcuraStem:

Shortcuts

Want your practice to be the top-listed Clinic in Monrovia?